[go: up one dir, main page]

WO2015119575A3 - Improved method, combination and/or composition for inducing cardiomyocyte or neuronal differentation - Google Patents

Improved method, combination and/or composition for inducing cardiomyocyte or neuronal differentation Download PDF

Info

Publication number
WO2015119575A3
WO2015119575A3 PCT/SG2015/000032 SG2015000032W WO2015119575A3 WO 2015119575 A3 WO2015119575 A3 WO 2015119575A3 SG 2015000032 W SG2015000032 W SG 2015000032W WO 2015119575 A3 WO2015119575 A3 WO 2015119575A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
combination
improved method
neuronal
differentation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SG2015/000032
Other languages
French (fr)
Other versions
WO2015119575A2 (en
Inventor
Se Ngie Winston SHIM
Ashish Mehta
Chrishan JA RAMACHANDRA
En Hou Philip WONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Singapore Health Services Pte Ltd
Original Assignee
Singapore Health Services Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Services Pte Ltd filed Critical Singapore Health Services Pte Ltd
Publication of WO2015119575A2 publication Critical patent/WO2015119575A2/en
Publication of WO2015119575A3 publication Critical patent/WO2015119575A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to an improved method for inducing cardiomyocyte or neuronal differentiation using a combination and/or composition of factors. The present invention also includes the combination and/or composition of factors. For example, the factors comprise at least one p38 mitogen-activated protein kinase (p38-MAPK) inhibitor; at least one immunosuppressant; at least one Wnt modulator; and at least one kinase modulator.
PCT/SG2015/000032 2014-02-06 2015-02-05 Improved method, combination and/or composition for inducing cardiomyocyte or neuronal differentation Ceased WO2015119575A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG2014010649 2014-02-06
SG2014010649 2014-02-06

Publications (2)

Publication Number Publication Date
WO2015119575A2 WO2015119575A2 (en) 2015-08-13
WO2015119575A3 true WO2015119575A3 (en) 2016-06-23

Family

ID=53778578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2015/000032 Ceased WO2015119575A2 (en) 2014-02-06 2015-02-05 Improved method, combination and/or composition for inducing cardiomyocyte or neuronal differentation

Country Status (1)

Country Link
WO (1) WO2015119575A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021119209A1 (en) * 2019-12-09 2021-06-17 Wisconsin Alumni Research Foundation In vitro expansion of dopaminergic subtype neuronal progenitors derived from pluripotent stem cells
EP4163365A4 (en) * 2020-06-09 2024-07-17 Myoridge Co. Ltd. METHOD FOR PRODUCING A CARDIOMYOCYTE POPULATION, METHOD FOR CULTIVATION OF CARDIOMYOCYTES, CARDIOMYOCYTE POPULATION, TRANSPLANT MATERIAL, MULTINUCLEATE CARDIOMYOCYTE AND KIT FOR CULTIVATION OF CARDIOMYOCYTES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080187494A1 (en) * 2005-09-12 2008-08-07 Es Cell International Pte Ltd Cardiomyocyte Production
WO2010144696A1 (en) * 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
WO2012067266A1 (en) * 2010-11-17 2012-05-24 Kyoto University Cardiomyocyte- and/or cardiac progenitor cell-proliferating agent and method for proliferating cardiomyocytes and/or cardiac progenitor cells
WO2014025315A1 (en) * 2012-08-07 2014-02-13 Singapore Health Services Pte Ltd Method, combination and/or composition for inducing cardiomyocyte differentation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080187494A1 (en) * 2005-09-12 2008-08-07 Es Cell International Pte Ltd Cardiomyocyte Production
WO2010144696A1 (en) * 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
WO2012067266A1 (en) * 2010-11-17 2012-05-24 Kyoto University Cardiomyocyte- and/or cardiac progenitor cell-proliferating agent and method for proliferating cardiomyocytes and/or cardiac progenitor cells
WO2014025315A1 (en) * 2012-08-07 2014-02-13 Singapore Health Services Pte Ltd Method, combination and/or composition for inducing cardiomyocyte differentation

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
BIKKAVILI RK ET AL.: "p38 mitogen-activated protein kmase regulates canonical Wnt- betacatenin signaling by inactivation of GSK3beta.", J CELL SCI., vol. 121, 1 November 2008 (2008-11-01), pages 3598 - 3607 *
BURRIDGE PW ET AL.: "Production of de novo cardiomyocytes:human pluripotent stem cell differentiation and direct reprogramming.", CELL STEM CELL, vol. 10, no. 1, 6 January 2012 (2012-01-06), pages 16 - 28, XP028434719, DOI: doi:10.1016/j.stem.2011.12.013 *
CAI J ET AL.: "BMP and TGF-beta pathway mediators are critical upstream regulators of Wnt signaling during midbrain dopamine differentiation in human pluripotent stem cells.", DEV BIOL., vol. 376, no. 1, 1 April 2013 (2013-04-01), pages 62 - 73, XP028988428, DOI: doi:10.1016/j.ydbio.2013.01.012 *
CHEN A ET AL.: "Considerations in designing systems for large scale production of human cardiomyocytes from pluripotent stem cells.", STEM CELL RES THER., vol. 5, no. 1, 21 January 2014 (2014-01-21), pages 12, XP021208883, DOI: doi:10.1186/scrt401 *
FARNSWORTH SL ET AL.: "Directed neural differentiation of induced pluripotent stem cells from non-human primates.", EXP BIOL MED (MAYWOOD)., vol. 238, no. 3, March 2013 (2013-03-01), pages 276 - 284 *
GAUR M ET AL.: "Timed inhibition of p38MAPK directs accelerated differentiation of human embryonic stem cells into cardiomyocytes.", CYTOTHERAPY., vol. 12, no. 6, October 2010 (2010-10-01), pages 807 - 817, XP055196533, DOI: doi:10.3109/14653249.2010.491821 *
GRAICHEN R ET AL.: "Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK.", DIFFERENTIATION. 2008 APR;, vol. 76, no. 4, 15 November 2007 (2007-11-15), pages 357 - 370, XP026772221, DOI: doi:10.1111/j.1432-0436.2007.00236.x *
HUNT J ET AL.: "Cyclosporin A has direct effects on adult neural precursor cells.", J NEUROSCI., vol. 30, no. 8, 24 February 2010 (2010-02-24), pages 2888 - 2896 *
KUMA Y ET AL.: "BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo.", J BIOL CHEM., vol. 280, no. 20, 20 May 2005 (2005-05-20), pages 19472 - 19479, XP007913553, DOI: doi:10.1074/jbc.M414221200 *
LIAN X ET AL.: "Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling.", PROC NATL ACAD SCI USA., vol. 109, no. 27, 3 July 2012 (2012-07-03), pages E1848 - E1857, XP055053519, DOI: doi:10.1073/pnas.1200250109 *
MA L ET AL.: "Mitogen-activated protein kinase p38 regulates the Wnt/cyclic GMP/Ca2+ non-canonical pathway.", J BIOL CHEM., vol. 282, no. 39, 28 September 2007 (2007-09-28), pages 28980 - 28990, XP055196569, DOI: doi:10.1074/jbc.M702840200 *
SMITH JL ET AL.: "Targeting combinatorial transcriptional complex assembly at specific modules within the interleukin-2 promoter by the immunosuppressant SB203580.", J BIOL CHEM., vol. 278, no. 42, 17 October 2003 (2003-10-17), pages 41034 - 41046, XP055196570, DOI: doi:10.1074/jbc.M305615200 *
UOSAKI H ET AL.: "Identification of chemicals inducing cardiomyocyte proliferation in developmental stage-specific manner with pluripotent stem cells.", CIRC CARDIOVASC GENET. 2013 DEC;, vol. 6, no. 6, pages 624 - 633, XP009177572, DOI: doi:10.1161/CIRCGENETICS.113.000330 *
VARADARAJAN, S: "p38 MAPKs coordinately regulate distinct phases of autophagy and lysosomal biogenesis.", PROQUEST, 2011 *
YAN P ET AL.: "Cyclosporin-A potently induces highly cardiogenic progenitors from embryonic stem cells.", BIOCHEM BIOPHYS RES COMMUN., vol. 379, no. 1, 30 January 2009 (2009-01-30), pages 115 - 120, XP025770136, DOI: doi:10.1016/j.bbrc.2008.12.019 *
ZHU WZ ET AL.: "Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells.", CIRC RES., vol. 107, no. 6, 17 September 2010 (2010-09-17), pages 776 - 786 *

Also Published As

Publication number Publication date
WO2015119575A2 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
SG11202104326TA (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
ZA202103223B (en) Process for the preparation of (s)-nicotin from myosmine
IL286868A (en) Compositions and methods for inhibiting gene expression in the central nervous system
WO2018089261A3 (en) Compounds and methods for modulating interleukin-2-inducible t-cell kinase
AU2019382117A1 (en) Process for the preparation of (S)-nicotin from myosmine
MX2018013495A (en) INTEGRATED STRESS TRAIL MODULATORS.
HK1252158A1 (en) Masked anti-cd3 antibodies and methods of use
EP3253798A4 (en) Antibodies directed against lymphocyte activation gene 3 (lag-3)
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
MY191581A (en) Anti-pd-1 antibodies
WO2016070869A3 (en) Device for carrying out a capillary nanoprinting method, a method for carrying out capillary nanoprinting using the device, products obtained according to the method and use of the device
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
WO2018071910A3 (en) Anti-il1-rap antibodies
EP3102207A4 (en) 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis
IL283948A (en) Methods for the treatment of depression
WO2018071796A3 (en) Compositions and methods for identifying functional anti-tumor t cell responses
PL3525799T3 (en) Method for establishing, restoring, and preserving homeostasis of the ocular surface
WO2017120527A3 (en) Therapeutic compositions and methods for treating hepatitis b
ZA202005739B (en) Method for article authentication
EP3466952A4 (en) Novel inhibitor for flt3 kinase and uses thereof
HUE059123T2 (en) Printing system for printing substrates as well as method for operating the printing system
WO2016154329A3 (en) P38 map kinase inhibitors for treating friedreich's ataxia
WO2015119575A3 (en) Improved method, combination and/or composition for inducing cardiomyocyte or neuronal differentation
WO2015194970A3 (en) Method of treating or preventing multiple sclerosis using one or more neural regeneration peptides
WO2016069542A3 (en) Lactone compounds and methods of making and using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15745978

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15745978

Country of ref document: EP

Kind code of ref document: A2